Veracyte, Inc.
VCYT
$43.12
-2.86%
Veracyte, Inc. is a genomic diagnostics company that develops and commercializes molecular tests designed to help clinicians diagnose and treat cancer at pivotal decision points, with a portfolio spanning thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). The company occupies a specialized niche in the medical diagnostics and research industry, positioning itself as a high-value, evidence-driven testing platform rather than a broad laboratory services provider, with roughly 755 employees and a market capitalization near $4.8 billion. The current investor narrative centers on the durability of Veracyte's double-digit test volume growth, the margin leverage embedded in its decentralized, lab-light operating model, and the competitive intensity in the prostate and bladder cancer testing markets where rivals such as Natera are expanding their molecular residual disease and companion diagnostic footprints. Attention is also focused on the stock's sharp post-earnings volatility, with shares gapping lower in late July before staging a partial recovery, leaving investors to debate whether the pullback reflects a temporary growth scare or a more durable reset in expectations for the diagnostics growth story.…
VCYT
Veracyte, Inc.
$43.12
Related headlines
Investment Opinion: Should I buy VCYT Today?
Rating: Hold with a constructive bias. The core thesis is that Veracyte's debt-free balance sheet, 69.6% gross margins, and 0.31 PEG make the post-selloff valuation attractive, but the unresolved question of whether test volume growth has durably decelerated justifies waiting for confirmation. The analyst consensus is a buy (mean 1.62 across 12 analysts) with an average target of $58.42, implying 35.5% upside, and even the low target of $44.00 is above the current $43.12 — a configuration that argues the downside is largely priced in.
Supporting evidence is stacked on the valuation side: forward PE of 22.2x against trailing 50.1x implies earnings are expected to more than double to $2.38, PEG of 0.31 is deeply discounted relative to the growth embedded in that ramp, and EV/sales of 5.6x is reasonable for a 69.6% gross-margin diagnostics platform. The balance sheet is pristine with a current ratio of 8.15 and debt-to-equity of 0.03, and the stock has rebounded 12.0% over the past month versus SPY's 1.2%, producing +10.8% relative strength that suggests the July gap is being digested rather than extended. Against this, the -27.1% three-month return and -29.8% relative underperformance versus SPY show the market is still skeptical.
The biggest risks that could invalidate the thesis are a second consecutive earnings miss on test volume, Natera's bladder cancer expansion eroding Decipher Bladder share, and multiple compression from the 33.3x EV/EBITDA level if growth slows. This Hold would upgrade to Buy if the next quarterly print shows test volume re-acceleration and gross margin holding above 69%, or if the stock pulls back toward the $38-40 zone where the forward PE would approach 16-17x. It would downgrade to Sell if revenue growth decelerates below 10% or if Natera wins a major U.S. bladder cancer reimbursement win. On balance, the stock is fairly valued to modestly undervalued relative to its own history and growth profile, but not yet a compelling buy until the volume trajectory is confirmed.
Sign up to view all
VCYT 12-Month Price Forecast
The forward view is balanced: valuation math (0.31 PEG, 35.5% upside to the average target, debt-free balance sheet) argues the selloff has overshot, but the July earnings gap and Natera's expanding bladder cancer footprint argue expectations are still resetting. The base case (50% probability) sees a grind toward $44-58 as the earnings ramp to $2.38 materializes, while the bear case (25%) targets a retest of the $29.46 low if volume disappoints again. I would upgrade to bullish if the next quarterly print shows test volume re-acceleration with gross margin above 69%, and downgrade to bearish if revenue growth decelerates below 10% or Natera wins a major U.S. bladder reimbursement. With beta at 1.95 and a 39.2% max drawdown already observed, position sizing should reflect the wide outcome dispersion.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veracyte, Inc.'s 12-month outlook, with a consensus price target around $58.42 and implied upside of +35.5% versus the current price.
Average Target
$58.42
0 analysts
Implied Upside
+35.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$44 - $70
Analyst target range
Bulls vs Bears: VCYT Investment Factors
The bear case currently has stronger near-term evidence: the -22.5% July earnings gap, a -27.1% three-month return versus SPY's +2.7%, and Natera's expanding bladder cancer footprint all argue that expectations are still resetting. However, the bull case is anchored in harder valuation math — a 0.31 PEG, 35.5% upside to the average analyst target, and a debt-free balance sheet with 69.6% gross margins — suggesting the selloff has created a favorable risk/reward for patient investors. The single most important tension is whether the post-earnings deceleration in test volume growth is a one-quarter air pocket or the start of a durable slowdown; if the next print shows volumes re-accelerating, the stock likely re-rates toward the $58 average target, but a second consecutive miss would validate the bear thesis and pressure shares toward the $44 low target. Until that data point arrives, the debate is genuinely balanced, with the edge going to the bulls only on a risk-adjusted, 12-month view.
Bullish
- Analyst consensus buy with 35% upside: All 12 covering analysts rate VCYT a buy (recommendation_mean 1.62), with an average target of $58.42 versus the current $43.12 — a 35.5% implied upside. Even the lowest target of $44.00 sits 2.0% above the current price, meaning the entire analyst range is above the market, a rare configuration that suggests sentiment has overshot to the downside.
- PEG of 0.31 signals deep growth discount: With a trailing PE of 50.1x but a PEG ratio of just 0.31, the market is paying very little per unit of expected earnings growth. Forward PE of 22.2x against consensus EPS of $2.38 implies earnings are expected to more than double from the trailing $0.86, a compression in multiple that is unusually steep for a diagnostics franchise with 69.6% gross margins.
- Fortress balance sheet with 8.1x current ratio: A current ratio of 8.15 and debt-to-equity of just 0.03 mean Veracyte carries essentially no leverage and ample liquidity. This gives the company the financial runway to absorb competitive pressure in prostate and bladder testing, fund evidence-generation studies, and pursue tuck-in acquisitions without dilution or covenant risk.
- High-margin, lab-light model drives operating leverage: Gross margin of 69.6% and operating margin of 14.3% demonstrate that incremental test volume flows through at attractive incremental margins. Net margin of 12.8% on a $4.8B market cap implies roughly $300M+ in annual revenue at current PS of 6.4x, and every point of margin expansion on growing volume materially lifts EPS.
Bearish
- July earnings gap erased 22% in one session: On 2026-07-31 the stock collapsed from $59.78 to $46.32, a -22.5% single-day move that has not been recovered — the current $43.12 is still 27.9% below the 52-week high of $60.91. This is the market's verdict that the growth trajectory disappointed, and the failure to reclaim even $48 since then signals a durable reset in expectations rather than a temporary scare.
- Valuation remains rich on cash flow and EBITDA: EV/EBITDA of 33.3x and price-to-cash-flow of 24.3x are premium multiples that leave little room for execution error. Even after the drawdown, PS of 6.4x and EV/sales of 5.6x price in continued double-digit growth; any deceleration in test volume would compress these multiples toward the mid-single digits.
- Natera expanding into bladder cancer globally: Natera's Signatera won Japan PMDA approval as a bladder cancer companion diagnostic in September 2026 — its second PMDA approval in three months — directly threatening Veracyte's Decipher Bladder franchise. Natera's MRD leadership and international regulatory momentum could cap Veracyte's bladder revenue growth before it scales.
- Extreme volatility with beta of 1.95: A beta of 1.947 means VCYT amplifies market moves roughly twofold, and the 39.2% max drawdown over the period confirms the stock can lose nearly 40% from a peak. For a company with only $0.02 in trailing EPS, earnings visibility is thin and sentiment-driven repricing is severe, as the July gap demonstrated.
VCYT Technical Analysis
Beta
1.95
1.95x market volatility
Max Drawdown
-39.2%
Largest decline past year
52-Week Range
$29-$61
Price range past year
Annual Return
+20.4%
Cumulative gain past year
| Period | VCYT Return | S&P 500 |
|---|---|---|
| 1m | +12.0% | +0.2% |
| 3m | -27.1% | +2.9% |
| 6m | +27.6% | +8.4% |
| 1y | +20.4% | +14.9% |
| ytd | +1.7% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
Valuation Analysis: Is VCYT Overvalued?
PE
50.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on Veracyte's thin GAAP profitability and the steepness of its forward earnings ramp. Trailing EPS of $0.02 and ROE of 5.1% mean the company has almost no cushion if reimbursement or volume trends soften, while the consensus forward EPS of $2.38 requires a dramatic margin step-up that depends on operating leverage materializing from the 69.6% gross margin base. Revenue concentration is another vulnerability: the portfolio leans on Afirma (thyroid) and Decipher Prostate, and a reimbursement cut or competitive share loss in either franchise would hit a revenue base of roughly $300M (implied by the 6.4x PS on a $4.8B market cap) disproportionately. The balance sheet itself is a strength — current ratio of 8.15 and debt-to-equity of 0.03 — so the financial risk is earnings volatility, not solvency.
Market and competitive risks are elevated by the stock's premium multiples and high beta. EV/EBITDA of 33.3x and price-to-cash-flow of 24.3x leave VCYT exposed to multiple compression if growth decelerates, and the 1.95 beta means any sector rotation out of high-multiple healthcare diagnostics would be amplified. The most concrete competitive threat is Natera, whose Signatera secured Japan PMDA approval as a bladder cancer companion diagnostic in September 2026 — its second PMDA approval in three months — directly contesting Veracyte's Decipher Bladder franchise and reinforcing Natera's MRD leadership. Regulatory and reimbursement headwinds are a persistent sector risk, and the July 31 earnings gap (-22.5% in one session) shows how quickly sentiment can reverse when growth expectations are not met.
The worst-case scenario is a second consecutive quarter of disappointing test volume growth combined with Natera gaining bladder cancer share, which would trigger analyst downgrades and compress the forward PE from 22.2x toward the mid-teens. In that chain of events, the stock would likely retest the 52-week low of $29.46 — a -31.7% decline from the current $43.12 — and could undershoot toward the $29-30 area given the 39.2% max drawdown already observed. Even the analyst low target of $44.00 offers no downside protection since it sits above the current price, meaning the market has already priced below the most bearish published estimate. An investor could realistically lose 30-35% from current levels in this adverse scenario.
FAQ
The most severe risk is company-specific execution: a second consecutive quarter of disappointing test volume growth after the -22.5% July 31 earnings gap would likely trigger downgrades and a retest of the $29.46 low. Second is competitive risk from Natera, whose Signatera won Japan PMDA approval as a bladder cancer companion diagnostic in September 2026, directly threatening the Decipher Bladder franchise. Third is valuation risk: EV/EBITDA of 33.3x and price-to-cash-flow of 24.3x leave little room for error, and with a beta of 1.95, any rotation out of high-multiple healthcare names would be amplified. Fourth is financial/earnings risk: trailing EPS of $0.02 and ROE of 5.1% mean the forward $2.38 EPS ramp is unproven, and a stall would compress the 22.2x forward PE sharply.
The 12-month forecast has three scenarios: a base case (50% probability) of $44-58 as earnings ramp toward $2.38 and the stock grinds toward the analyst average target of $58.42; a bull case (25%) of $58-70 if test volume re-accelerates and multiple expansion toward 28-30x forward PE is justified; and a bear case (25%) of $29.46-44 if a second volume miss triggers downgrades and a retest of the 52-week low. The base case is most likely because it assumes the consensus EPS ramp is achieved while competitive overhang from Natera caps multiple expansion. The key assumption behind the base case is that gross margin holds near 69.6% and no major reimbursement cuts hit Afirma or Decipher Prostate.
VCYT is modestly undervalued relative to its growth profile but not cheap on absolute multiples. The trailing PE of 50.1x and EV/EBITDA of 33.3x are premium levels, but the forward PE of 22.2x and PEG of 0.31 tell a different story — the market is paying a reasonable price for expected earnings growth to $2.38. PS of 6.4x and EV/sales of 5.6x are fair for a 69.6% gross-margin diagnostics platform, and the 2.53 price-to-book is modest given the debt-free balance sheet. The market appears to be pricing in skepticism about the earnings ramp rather than euphoria, which is why the stock sits 27.9% below its 52-week high of $60.91. If the $2.38 forward EPS is achieved, the current price embeds a discount to the analyst average target of $58.42.
From a risk/reward perspective, VCYT offers a favorable asymmetry: the average analyst target of $58.42 implies 35.5% upside, and even the lowest target of $44.00 sits above the current $43.12, meaning the entire published analyst range is above the market. The valuation is supported by a 0.31 PEG and 22.2x forward PE against a 50.1x trailing multiple, implying earnings are expected to more than double to $2.38. However, the biggest downside risk is a second consecutive test volume miss, which could send shares to the 52-week low of $29.46 — a -31.7% move. It is a good buy for investors with a 2-3 year horizon who can tolerate a 1.95 beta and want exposure to genomic diagnostics at a discounted multiple, but only with position sizing that accounts for the wide outcome dispersion and ideally after confirmation of volume re-acceleration in the next print.
VCYT is better suited to long-term holding than short-term trading. The company is in a growth stage with a 0% dividend yield and a 1.95 beta, meaning short-term price action is dominated by earnings volatility — the -22.5% single-day July gap and 39.2% max drawdown illustrate the risk of trading around catalysts. Earnings visibility is improving but still thin at $0.02 trailing EPS, so the forward $2.38 consensus needs multiple quarters to prove out. A concrete suggested minimum holding period is 24-36 months, allowing time for the test volume trajectory to be confirmed and for the earnings ramp to materialize. Short-term traders could trade the $40-48 range, but the risk/reward favors patient accumulation near the lower end.